Market Overview

Roth's Pantginis Downgrades Sunesis, Price Target Smashed To $1.00 On 'Many Outstanding Questions'


In a report published Friday, Roth Capital Partners analyst Joseph Pantginis downgraded the rating on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) from Buy to Sell, while reducing the price target from $5.50 to $1.

"Sunesis provided the much anticipated regulatory updates from both the FDA and EMA with mixed results, though we believe the net outcome is poor for the vosaroxin investment case. The FDA said "nay" regarding a vosaroxin NDA filing with more data required and the EMA Rapporteurs said "yay" regarding an MAA filing," analyst Joseph Pantginis wrote.

Pantginis pointed out that there were "too many open questions for vosaroxin looking forward." There was "an apparent switch in tenor" by the FDA, since it had approved other drugs on subpopulation data. Since there was "no visibility" on the way ahead for vosaroxin in the US, it cannot be included in Roth Capital's valuation, which now would focus "only on the E.U. opportunity, for which we only assign a 15% chance of success (down from 20%)," the report said.

"While the company tried to provide some information regarding early pipeline assets, we do not believe the Street is prepared to place value on them," Pantginis mentioned.

Latest Ratings for SNSS

Dec 2018Initiates Coverage OnNeutral
Dec 2017UpgradesMarket PerformOutperform
Dec 2017DowngradesOutperformMarket Perform

View More Analyst Ratings for SNSS
View the Latest Analyst Ratings

Posted-In: ROTH Capital PartnersAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (SNSS)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Benzinga's Top Downgrades

Benzinga's Top Upgrades